Skip to main content

Table 2 Baseline characteristics of the ankylosing spondylitis patients treated with infliximab according to the response BASDAI50 after 6 months of infliximab

From: Body mass index influences the response to infliximab in ankylosing spondylitis

  Yes
(n= 77)a
No
(n= 62)a
Pvalue
Age (years), median (IQR) 39.4 (32.0 -50.0) 44.8 (38.2-53.0) 0.0469
Gender (% males) 72.7 51.6 0.0102
Disease duration (years), median (IQR) 8.0 (4.0-14.0) 6.0 (3.0-12.0) 0.1966
BMI (kg/m2) 24.4 (21.9-26.8) 28.7 (25.6-31.6) < 0.0001
HLAB27 (% of patients) 73.3 56.9 0.0470
Δweight (kg), median (IQR) -1.0 (-2.0-2.0) 0.0 (-2.0-3.0) 0.4948
Baseline CRP (mg/dl), median (IQR) 14.0 (5.0-26.0) 6.6 (3.0-13.0) 0.0039
  1. aTwo patients withdrew from IFX therapy (lack of response and serious adverse event) and BASDAI50 lacking data for 14 AS patients
  2. BASDAI50, 50% improvement in the Bath Ankylosing Spondylitis Disease Activity Index; BMI, body mass index; CRP, C-reactive protein; IQR, interquartile range.